Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220963 | 1.00 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL20126461 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL21728798 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL19466410 | 0.92 | FURIN (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL21318749 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL25098213 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL20283603 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL19485764 | 0.92 | FURIN (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL22268356 | 0.91 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL24220965 | 0.91 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129614-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-11833120-B2 | Binding protein drug conjugates comprising anthracycline derivatives | NBE-THERAPEUTICS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| WO-2023078464-A1 | EPSILON-POLY-L-LYSINE-BASED DRUG CONJUGATE, INTERMEDIATE THEREOF, AND APPLICATION THEREOF | 上海弼领生物技术有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210322561-A1 | BINDING PROTEIN DRUG CONJUGATES COMPRISING ANTHRACYCLINE DERIVATIVES | NBE-THERAPEUTICS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | CHINOOK THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| EP-2707031-B1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| US-20190125892-A1 | BINDING PROTEIN DRUG CONJUGATES COMPRISING ANTHRACYCLINE DERIVATIVES | NBE-THERAPEUTICS AG (CH) | 2019-05-02 | — | — | US | disclosed |
| US-10188745-B2 | Binding protein drug conjugates comprising anthracycline derivatives | NBE-THERAPEUTICS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-9951141-B2 | Antibody-drug conjugates, their preparation and their therapeutic use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20180055948-A1 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same | REMEGEN CO., LTD. (CN) | 2018-03-01 | — | — | US | disclosed |
| US-20170360953-A1 | BINDING PROTEIN DRUG CONJUGATES COMPRISING ANTHRACYCLINE DERIVATIVES | NBE-THERAPEUTICS AG (CH) | 2017-12-21 | — | — | US | disclosed |
| US-20170121413-A1 | ANTIBODY-DRUG CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | REGENERON PHARMACEUTICALS, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125892-A1 | BINDING PROTEIN DRUG CONJUGATES COMPRISING ANTHRACYCLINE DERIVATIVES | ABCC1, BCR, HNRNPU | SIRT2 2594/4885SIRT1 3694/4885SIRT3 2884/4885 |
| US-11833120-B2 | Binding protein drug conjugates comprising anthracycline derivatives | ABCC1, ABCB1, ABCC2 | SIRT2 2153/4885SIRT1 3536/4885SIRT3 2455/4885 |
| US-20210322561-A1 | BINDING PROTEIN DRUG CONJUGATES COMPRISING ANTHRACYCLINE DERIVATIVES | ABCC1, BCR, ABCC2 | SIRT2 2534/4885SIRT1 3645/4885SIRT3 2887/4885 |
| US-20210170043-A1 | DC-SIGN ANTIBODY CONJUGATES COMPRISING STING AGONISTS | STING1, TLR9, TLR3 | SIRT2 2294/4885SIRT1 2438/4885SIRT3 2909/4885 |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | STING1, PDCD1LG2, CD274 | SIRT2 3490/4885SIRT1 3197/4885SIRT3 4019/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | SIRT2 3490/4885SIRT1 3197/4885SIRT3 4019/4885 |
| US-20170121413-A1 | ANTIBODY-DRUG CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CD22, CD47, CD2 | SIRT2 4451/4885SIRT1 4412/4885SIRT3 4767/4885 |
| US-20180055948-A1 | Covalent Linkers in Antibody-Drug Conjugates and Methods of Making and Using the Same | DHFR, FCGR1A, ADCY4 | SIRT2 823/4885SIRT1 868/4885SIRT3 1139/4885 |
| US-10188745-B2 | Binding protein drug conjugates comprising anthracycline derivatives | ABCC1, BCR, HNRNPU | SIRT2 2594/4885SIRT1 3694/4885SIRT3 2884/4885 |
| US-20170360953-A1 | BINDING PROTEIN DRUG CONJUGATES COMPRISING ANTHRACYCLINE DERIVATIVES | ABCC1, BCR, HNRNPU | SIRT2 2594/4885SIRT1 3694/4885SIRT3 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.